ABIVAX (EPA:ABVX) | WebDisclosure

Basculer en Français

10811	Companies
234208	Keywords
162977	Articles
125205	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 07/25/2025 at 08:00, 1 year ago

Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l'Offre à 747,5 M$ (637,5 M€)
Abivax a exercé intégralement l’option de souscription d’ADS supplémentaires, portant le produit brut de l'Offre à 747,5 M$ (637,5 M€), soutenant le développement de thérapies pour maladies inflammatoires

Biotechnologie Abivax Maladies Inflammatoires Souscription Produit Brut
PRESS RELEASE

published on 07/25/2025 at 08:00, 1 year ago

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax announces full exercise of underwriters’ option to purchase additional ADSs, bringing gross proceeds of offering to $747.5M (€637.5M). Company to apply net proceeds to identified use of funds

Abivax Underwriters ADSs Offering Proceeds
BRIEF

published on 07/24/2025 at 14:45, 1 year ago

Abivax's $650M Public Offering of ADS

Biotechnology Abivax Capital Increase Public Offering Ads
BRIEF

published on 07/24/2025 at 14:45, 1 year ago

Abivax lance une offre publique d'ADS de 650 millions de dollars

Biotechnologie Abivax Augmentation De Capital Offre Publique PUBLICITÉS
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year ago

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements thérapeutiques pour les maladies inflammatoires chroniques

Euronext Paris Biotechnologie Abivax Traitements Thérapeutiques Maladies Inflammatoires
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year ago

Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares
Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares pour financer le développement de thérapies biotechnologiques. Details de l'offre, stabilisation et prévisions financières

Biotechnologie Abivax Ads Offre Publique Modalités Définitives
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year ago

Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax announces the trading resumption of its ordinary shares on Euronext Paris after a temporary halt for a public offering confirmation and pricing announcement

Euronext Paris Abivax Public Offering Clinical-stage Biotechnology Trading Resumption
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year ago

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements pour les maladies inflammatoires chroniques

Euronext Paris Biotechnologie Abivax Négociations Traitements
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year ago

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
Abivax announces pricing of $650M (€554M) public offering of American Depositary Shares to fund clinical development and working capital, with expected closing on July 28, 2025

Abivax Clinical Development Public Offering Pricing Closing
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year ago

Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares
Abivax annonce les modalités de son offre de 650M$ d'American Depositary Shares pour financer des développements cliniques. Stabilisation et options incluses

Abivax Développement Clinique Offre Publique Stabilisation American Depositary Shares

Accesswire

Published on 08/07/2026 at 14:17, 3 hours 17 minutes ago

NuRAN Wireless Increases Series A Preferred Share Financing to C$7.6 Million and Announces Debt Settlements
Published on 08/07/2026 at 13:00, 4 hours 34 minutes ago

Gold Terra Announces Start of Drilling on the Campbell Shear Northern Zone 103N Extension to Expand 2026 MRE of Inferred 595,000 Ounces, Con Mine, Yellowknife, NWT
Published on 08/07/2026 at 00:45, 16 hours 49 minutes ago

NXT Energy Solutions Announces Second Quarter 2026 Results
Published on 08/06/2026 at 23:15, 18 hours 19 minutes ago

LNG Energy Group Announces Issuance of Second Partial Revocation Order and Further Details on Private Placement Financing
Published on 08/06/2026 at 22:15, 19 hours 19 minutes ago

Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada

View all ACCESSWIRE

EQS Group

Published on 08/07/2026 at 16:51, 43 minutes ago

Issue of Equity
Published on 08/07/2026 at 16:34, 59 minutes ago

Net Asset Value(s)
Published on 08/07/2026 at 15:39, 1 hour 55 minutes ago

Predictiv AI Inc. Hires Aktien Media for Internet Advertising Services
Published on 08/07/2026 at 15:16, 2 hours 18 minutes ago

Announcement pursuant to Art. 5 para 1 of Regulation (EU) No. 596/2014 in conjunction with Art. 2 para 1 of the Delegated Regulation (EU) 2016/1052 of the Commission
Published on 08/07/2026 at 15:06, 2 hours 28 minutes ago

Form 8.3 - The Vanguard Group, Inc.: SEGRO plc

Les Echos

Published on 08/07/2026 at 15:36, 1 hour 58 minutes ago

NRJ Group - Information relative aux droits de vote au 31.07.2026 (French & English)
Published on 08/07/2026 at 08:30, 9 hours 4 minutes ago

Disclosure of shares outstanding and voting rights - 07.08.2026
Published on 08/07/2026 at 08:30, 9 hours 4 minutes ago

Déclaration nombre d'actions et droits de vote - 07.08.2026
Published on 08/06/2026 at 18:26, 23 hours 8 minutes ago

Air Liquide voting rights as of July 31st 2026
Published on 08/06/2026 at 18:26, 23 hours 8 minutes ago

Air Liquide droits de vote au 31 juillet 2026

View all LES ECHOS COMFI WIRE